Navigation Links
ThromboGenics is Shortlisted for "Biotech Company of the Year" and "Licensing Deal of the Year" at Scrip Awards 2009
Date:9/11/2009

LEUVEN, Belgium, September 11 /PRNewswire-FirstCall/ --

- ThromboGenics' Significant Achievements Over the Last Year are Recognised in Nominations

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announced today that it has been shortlisted for both the "Biotech Company of the Year" and "Licensing Deal of the Year" awards at the Scrip Awards 2009. These nominations recognise the transformational year that ThromboGenics has had, and the progress it has made toward becoming a profitable, integrated Company focused on cutting edge ophthalmic medicines.

The Biotech Company of the Year award recognises the progress and achievement a biotech company has made within the last twelve months. During the period, ThromboGenics has started the pivotal transatlantic Phase III programme with microplasmin for back of the eye disease, signed a EUR500 million partnership deal with Roche for its novel anti-cancer antibody TB-403, and moved its novel anti-coagulant TB-402 into Phase II trials. TB-402 is another potential partnership opportunity. There are four other companies nominated in this category.

The Licensing Deal of the Year award acknowledges the achievement of a Company in signing a licensing deal that has both monetary and strategic benefits to all parties. ThromboGenics signed a major partnership deal with Roche for TB-403 under which the Company and co-development partner BioInvent received an upfront payment of EUR50 million, an additional EUR450 million in potential milestones, and double digit royalties on future product sales. There are four other licensing deals nominated in this category.

The Scrip Awards is one of the biotechnology and pharmaceutical industry's most prestigious and highly contested awards event. The event is in its fif
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
6. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
7. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
8. ThromboGenics Announces 2007 Full Year Results
9. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
10. ThromboGenics N.V. - Business Update
11. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... 24, 2014 Research and Markets ... by Product , Research Area & by End User ... offering. In this report, the global ... research areas, and end users. The product segments of ... instruments & consumables, kits, and reagents. The subsegments of ...
(Date:10/22/2014)... 2014 New test innovations will be the ... (IVD) test industry, especially as companies struggle with reimbursement ... more than 25 testing innovations in important disease areas ... IVD products. Kalorama details the new approaches its biennial survey ... In Vitro Diagnostic Tests , 9th Edition . ...
(Date:10/22/2014)... DUBLIN and BOSTON , ... ACT ), a leading global specialty pharmaceutical company, and ... been granted an exclusive option to acquire Rhythm,s wholly ... (RM-131), a peptide ghrelin agonist, for the treatment of ... Rhythm has completed a successful Phase 2 trial ...
(Date:10/22/2014)... (PRWEB) October 21, 2014 The North ... concerned market North America with analysis and forecast of ... 2013, and is expected to reach $623.6 million by ... 2018. , Browse through the TOC of the North ... of the in-depth analysis provided. This also provides a ...
Breaking Biology Technology:Global Epigenetics (VLA, WBA, NBA, RTA, Rotary-Wing Aircraft) Market - Forecast to 2019 2Global Epigenetics (VLA, WBA, NBA, RTA, Rotary-Wing Aircraft) Market - Forecast to 2019 3Report: Radical New IVD Test Approaches Key To Growth 2Report: Radical New IVD Test Approaches Key To Growth 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 2The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 4
... ), a biopharmaceutical company focused on the treatment of obesity, today announced that the Company will be speaking ... , , Date:  May ... Time:  8:30am Pacific Time , , , ... , , ...
... HONG KONG , May 10 /PRNewswire-FirstCall/ ... Cypress Biosciences ("Cypress"), its development partner for Indaflex, that ... the termination of all Indaflex activity in the ... Chinese market. AlphaRx is working diligently with its regulatory ...
... NEW YORK , May 10 /PRNewswire-Asia-FirstCall/ -- ... pharmaceutical,company dedicated to improving health through the development, manufacture and,commercialization of a broad ... the first quarter ended March,31, 2010 . , ... First Quarter 2010 Financial Performance , ...
Cached Biology Technology:Orexigen(R) Therapeutics to Speak at Ninth Annual JMP Securities Research Conference 2American Oriental Bioengineering Reports First Quarter 2010 Financial Results 2American Oriental Bioengineering Reports First Quarter 2010 Financial Results 3American Oriental Bioengineering Reports First Quarter 2010 Financial Results 4American Oriental Bioengineering Reports First Quarter 2010 Financial Results 5American Oriental Bioengineering Reports First Quarter 2010 Financial Results 6American Oriental Bioengineering Reports First Quarter 2010 Financial Results 7American Oriental Bioengineering Reports First Quarter 2010 Financial Results 8
(Date:10/17/2014)... release is available in German . ... a very few drugs. When treating overdoses, doctors are often ... especially difficult if there is a combination of drugs involved. ... and accidentally swallows his grandmother,s pills? ETH professor Jean-Christophe Leroux ... to find an answer to this question. "The task was ...
(Date:10/16/2014)... thinking on how the bowel lining develops and, in ... cancer starts. , The researchers produced evidence that stem ... that are a feature of the bowel lining, and ... development, a controversial finding as scientists are still divided ... technologies, Dr Chin Wee Tan and Professor Tony Burgess ...
(Date:10/16/2014)... SHELTON, Conn. , October 16, 2014 ... ("NXT-ID" or the "Company"), a biometric authentication company focused ... present its leading edge technologies including Wocket™, the Smart ... Review® (FiRe) Conferenece. FiRe is a leading global conference ... Hosted by Mark Anderson , founder ...
Breaking Biology News(10 mins):Emergency aid for overdoses 2Emergency aid for overdoses 3Cryptic clues drive new theory of bowel cancer development 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3
... next five years for a pilot project to assess ... conditions can and should become a routine part of ... launched today by the National Institutes of Health to ... as part of, or instead of, the current newborn screening ...
... September 5, 2013, Shenzhen, China BGI in collaboration ... other Chinese institutes, have completed the genome sequencing of ... infectious disease tuberculosis (TB). The study published online in ... researchers to better understand the genetic basis underlying drug ...
... known for some time that the blood vessels that transport ... are more than just bodily pipelines. Arterioles and capillaries, the ... flow of the blood they,re carrying. Biomedical engineers at Drexel ... that explains just how they do it. The team, ...
Cached Biology News:UCSF receives $4.5M to study value of gene sequencing in newborns 2UCSF receives $4.5M to study value of gene sequencing in newborns 3UCSF receives $4.5M to study value of gene sequencing in newborns 4Drug resistance-associated genes: A cornerstone for the control and protection against tuberculosis 2Drexel researchers looking inside vessels to understand blood's ebb and flow 2
Secure-Seal™ hybridization chamber gasket, eight chambers, 9 mm diameter, 0.8 mm deep *set of 20*...
RAT ANTI MOUSE F4/80 ANTIGEN:BIOTIN Immunogen: Thioglycollate stimulated peritoneal macrophages from C57/BL mice...
ANTI PIG LDH H4...
... ideal for use in refrigerators, freezers, or liquid nitrogen. ... colors allow for color coding to project, user, lab, ... or promote cool air circulation. Supplied with 10 x ... Box dimensions: 13 x 13 x 5.1 ...
Biology Products: